Grebien et al. have shown that OICR-9429 can decrease the viability of C/EBPα-mutated AML cells, supporting its potential anticancer effect on non-MLL-rearranged leukemia and solid tumors [204]. This evidence concerns the gene KMT2A and leukemia.